↓ Skip to main content

Dove Medical Press

Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date

Overview of attention for article published in OncoTargets and therapy, March 2023
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
1 news outlet
twitter
4 X users
patent
1 patent

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
17 Mendeley
Title
Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date
Published in
OncoTargets and therapy, March 2023
DOI 10.2147/ott.s400563
Pubmed ID
Authors

Leticia Varella, Massimo Cristofanilli

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Other 2 12%
Researcher 2 12%
Student > Master 1 6%
Professor > Associate Professor 1 6%
Unknown 11 65%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 3 18%
Biochemistry, Genetics and Molecular Biology 2 12%
Medicine and Dentistry 1 6%
Unknown 11 65%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2023.
All research outputs
#2,513,307
of 25,584,565 outputs
Outputs from OncoTargets and therapy
#65
of 2,967 outputs
Outputs of similar age
#49,847
of 423,796 outputs
Outputs of similar age from OncoTargets and therapy
#1
of 14 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,967 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 423,796 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.